The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis

MLA

Kristine Paridaens, et al. “The Continuing Value of Mesalazine as First-Line Therapy for Patients with Moderately Active Ulcerative Colitis.” Frontiers in Gastroenterology, vol. 3, June 2024. EBSCOhost, https://doi.org/10.3389/fgstr.2024.1335380.

APA

Kristine Paridaens, Matthew J. Freddi, & Simon P. L. Travis. (2024). The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis. Frontiers in Gastroenterology, 3. https://doi.org/10.3389/fgstr.2024.1335380

Chicago

Kristine Paridaens, Matthew J. Freddi, and Simon P. L. Travis. 2024. “The Continuing Value of Mesalazine as First-Line Therapy for Patients with Moderately Active Ulcerative Colitis.” Frontiers in Gastroenterology 3 (June). doi:10.3389/fgstr.2024.1335380.